Marpai Seeks 'Blank Check' Preferred Stock Authority

Ticker: MRAI · Form: DEF 14A · Filed: Jul 3, 2025 · CIK: 1844392

Marpai, INC. DEF 14A Filing Summary
FieldDetail
CompanyMarpai, INC. (MRAI)
Form TypeDEF 14A
Filed DateJul 3, 2025
Risk Levelhigh
Sentimentbearish

Sentiment: bearish

Topics: Corporate Governance, Shareholder Dilution, Preferred Stock, Capital Structure, Proxy Statement, Risk Management, SEC Filings

Related Tickers: MRAI

TL;DR

**MRAI's move to authorize 'blank-check' preferred stock is a red flag for common shareholders, signaling potential future dilution and board control over capital structure.**

AI Summary

Marpai, Inc. (MRAI) has filed a DEF 14A for its annual meeting on August 27, 2025, at 9:30 a.m. EST in Tampa, FL. The company plans to elect six directors to its Board for a one-year term. A significant proposal is the ratification of UHY LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025. Most notably, Marpai seeks to amend its Second Amended and Restated Certificate of Incorporation to authorize 2,000,000 shares of 'blank-check preferred stock' with a $0.0001 par value. The Board will have sole discretion to determine the voting powers, preferences, and rights of these preferred shares. This move could provide Marpai with substantial flexibility for future capital raises or strategic transactions, potentially diluting existing common shareholders. The filing does not contain specific revenue or net income figures, focusing instead on governance and corporate structure changes.

Why It Matters

Marpai's proposal to authorize 2,000,000 shares of 'blank-check preferred stock' grants its Board significant power to raise capital or engage in strategic maneuvers without further shareholder approval for specific terms. This could be a double-edged sword: while it offers financial flexibility for growth or acquisitions, it also poses a substantial risk of dilution for existing common shareholders, as the Board can set the preferences and voting rights of these new shares. Investors need to weigh the potential for strategic growth against the risk of value erosion, especially in the competitive health and allied services sector where Marpai operates.

Risk Assessment

Risk Level: high — The authorization of 2,000,000 shares of 'blank-check preferred stock' with terms solely determined by the Board presents a high risk. This allows the Board to issue shares with superior voting rights or liquidation preferences, potentially diluting the economic and voting power of current common stockholders without requiring additional shareholder votes on the specific terms of each issuance.

Analyst Insight

Investors should carefully consider the implications of the 'blank-check' preferred stock authorization. Monitor future announcements regarding any issuance of these shares and their specific terms, as they could significantly impact common stock value. Consider voting against this proposal if shareholder protection is a primary concern.

Key Numbers

Key Players & Entities

FAQ

What is Marpai, Inc. proposing at its August 27, 2025 annual meeting?

Marpai, Inc. is proposing to elect six directors, ratify UHY LLP as its independent auditor, and most significantly, amend its Certificate of Incorporation to authorize 2,000,000 shares of 'blank-check preferred stock' with a $0.0001 par value.

What are the implications of Marpai authorizing 'blank-check preferred stock'?

Authorizing 'blank-check preferred stock' grants Marpai's Board of Directors sole discretion to determine the voting powers, preferences, and rights of these shares. This could lead to significant dilution of existing common shareholders' voting power and economic interest if the preferred shares are issued with superior terms.

Who is Marpai, Inc.'s independent registered public accounting firm for 2025?

Marpai, Inc.'s Audit Committee has appointed UHY LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, subject to shareholder ratification at the upcoming annual meeting.

When and where is Marpai, Inc.'s annual meeting of stockholders?

Marpai, Inc.'s annual meeting of stockholders will be held at 9:30 a.m. EST on Wednesday, August 27, 2025, at the company's U.S. office located at 615 Channelside Drive, Suite 207, Tampa, FL 33610.

How many directors will be elected to Marpai's Board of Directors?

Marpai, Inc. intends to elect six directors to serve on its Board of Directors for a one-year term that expires at the next annual meeting of stockholders, or until their successors are elected and qualified.

What is the par value of the proposed preferred stock for Marpai, Inc.?

The proposed preferred stock for Marpai, Inc. will have a par value of $0.0001 per share, as outlined in the amendment to the company's Second Amended and Restated Certificate of Incorporation.

Why is the authorization of preferred stock considered a risk for Marpai shareholders?

The authorization is risky because the Board can issue these 2,000,000 preferred shares with terms that could prioritize new investors over existing common shareholders, potentially impacting share price and control without further direct shareholder input on specific issuances.

What type of SEC filing is Marpai, Inc.'s 0001213900-25-061346?

Marpai, Inc.'s filing 0001213900-25-061346 is a Definitive Proxy Statement, specifically a DEF 14A, which is used to solicit shareholder votes for an annual or special meeting.

What is the primary business address for Marpai, Inc.?

Marpai, Inc.'s primary business address is 615 Channelside Drive, Suite 207, Tampa, FL 33602, which is also the location for their upcoming annual meeting.

What is the fiscal year end for Marpai, Inc.?

Marpai, Inc.'s fiscal year ends on December 31, as indicated in the company data section of the DEF 14A filing.

Industry Context

Marpai operates within the health and allied services sector, which is characterized by evolving regulatory landscapes and a growing demand for innovative healthcare solutions. The company's focus on technology-driven insurance solutions places it in a competitive environment with both established players and emerging InsurTech companies.

Regulatory Implications

The authorization of 'blank-check' preferred stock could lead to significant dilution for existing common shareholders if used for capital raises without commensurate value creation. Companies in the health services sector are also subject to various healthcare regulations, though this filing primarily addresses corporate governance.

What Investors Should Do

  1. Review the implications of 'blank-check' preferred stock authorization.
  2. Evaluate the proposed director nominees.
  3. Confirm ratification of UHY LLP as auditor.

Key Dates

Glossary

DEF 14A
A Definitive Proxy Statement filed with the SEC by public companies to solicit shareholder votes for annual meetings or other corporate actions. (This document outlines the proposals Marpai, Inc. is asking shareholders to vote on, including board elections and corporate structure changes.)
Blank-check preferred stock
Preferred stock where the board of directors has the authority to determine the specific rights, preferences, and voting powers of the shares after they are authorized. (Marpai is seeking authorization for 2,000,000 shares of this type of stock, giving the board significant flexibility for future capital raises or strategic transactions.)
Certificate of Incorporation
The foundational legal document that establishes a corporation and outlines its basic structure, powers, and purpose. (Marpai is proposing an amendment to this document to authorize the new class of preferred stock.)
Independent registered public accounting firm
An external audit firm hired by a company to conduct an independent examination of its financial statements. (Shareholders are being asked to ratify the appointment of UHY LLP as Marpai's auditor for the fiscal year ending December 31, 2025.)

Year-Over-Year Comparison

This filing is a proxy statement for the annual meeting and does not contain comparative financial performance data against the previous year. The primary focus is on proposed changes to the company's capital structure, specifically the authorization of 'blank-check' preferred stock, and routine governance matters like director elections and auditor ratification.

Filing Details

This Form DEF 14A (Form DEF 14A) was filed with the SEC on July 3, 2025 by Board of Directors regarding Marpai, Inc. (MRAI).

View full filing on EDGAR

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on Read The Filing